Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to determine the effect of dopamine agonist therapy on
insulin resistance in lean vs. obese women with polycystic ovary syndrome. Polycystic ovary
syndrome (PCOS) is a common metabolic abnormality in women. The diagnosis of PCOS relies on a
constellation of symptoms and signs (problems with ovulation, clinical and/or biochemical
signs of hyperandrogenism and cystic ovaries). Though not a diagnostic feature, insulin
resistance (IR) is a hallmark of PCOS and up to 80% women with PCOS have IR. Although IR is
more significant in obese women with PCOS, even lean women can be insulin resistant. No
current therapy addresses the problem of insulin resistance in PCOS. Studies have suggested a
dopamine deficiency in patients with PCOS, which may underlie the insulin resistance and may
have a pathogenetic role in the development of PCOS. No study to date has assessed the impact
of dopamine agonist therapy on IR in patients with PCOS.